- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00855361
A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)
April 26, 2013 updated by: Janssen Research & Development, LLC
A Pharmacokinetic, Pharmacodynamic and Short-term Safety Study of Single and Multiple Day Doses of Rabeprazole Sodium in Neonates and Pre-term Infants With a Corrected Age of Less Than 44 Weeks With a Presumptive Diagnosis of GERD
The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics, and the safety of rabeprazole sodium for the treatment of gastroesophageal reflux disease (GERD) in newborns and pre-term infants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a multi-center Phase I study in newborns and pre-term infants (less than 44 weeks at the time of the first dose).
The drug being studied is rabeprazole sodium, the active pharmaceutical ingredient in AcipHex.
This study will consist of two parts, Part 1 and Part 2. Each part will consist of three phases, a pre-treatment phase (screening of up to 7 days before the start of treatment), a treatment phase (up to 28 days) and a post treatment phase (at least 14 days, but no more than 21 days after the last dose of study drug).
The maximum study length for each patient will therefore be up to 8 weeks.
Patients will be monitored patients with a presumptive diagnosis of GERD and who need a feeding tube for enteral alimentation (complete or partial) in place and have been admitted to a newborn intensive care unit or step down unit.
The population pharmacokinetics (PK) results together with the pharmacodynamics (ie, pHmetry) data, the safety and tolerability data from Part 1 will be assessed to determine the two dose levels to be studied in Part 2 before the start of dosing.
Pharmacokinetics explores how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time.
Pharmacodynamics (PD) studies the action or effects a drug has on the body.
All patients in Part 1 will require pH monitoring for clinical management and undergo a 24-hour PD assessment (intraesophageal and intragastric pHmetry).
At least 12 patients in Part 2 (at least 6 patients from each dose group) will require pH monitoring and undergo the same PD assessment as patients in Part 1. Patients participating in the pHmetry assessment must be in need of this assessment for their clinical management in the opinion of the Principal Investigator.
The intraesophageal and intragastric 24-hour pH PD assessment in both Part 1 and Part 2 will be performed at baseline (Day -1) and after the first dose (Day 1) and fifth dose (Day 5).
Sampling for single dose blood level PK evaluations will be performed post-dose on Day 1. Sampling blood level evaluations at the presumed steady-state during multiple dosing will be performed on Day 5. Patients' safety will be monitored throughout the study.
At the end of the study, or if any patient prematurely discontinues his/her participation in the study, a safety evaluation will be performed at least 14 days, but no more than 21 days, after the final rabeprazole sodium dose.
During the course of the study, after consent each patient will have medical history, a physical, length, weight, vital signs, blood chemistry, and urinalysis.
Safety from baseline to the End of Study visit (post-treatment phase) will be evaluated by examining incidence, severity and relationship to the study drug and type of Adverse Events (AEs), urinalysis, physical examination and vital signs.
Patients will receive rabeprazole sodium as a single daily dose for up to 28 consecutive days.
Patients participating in Part 1 will receive 1.0 mg rabeprazole sodium administered by a nasogastric tube.
After four patients complete Part 1, their rabeprazole plasma levels will be assessed and the dose may be increased to 2.0 mg rabeprazole sodium.
The population PK results, together with the PD (ie, pHmetry) data, safety and tolerability data from Part 1 will be assessed to determine 2 doses in Part 2.
Study Type
Interventional
Enrollment (Actual)
69
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aachen, Germany
-
-
-
-
-
Bydgoszcz, Poland
-
Lublin Poland, Poland
-
Odz, Poland
-
Poznan N/A, Poland
-
-
-
-
-
Barnsley N/A, United Kingdom
-
Manchester, United Kingdom
-
Preston, United Kingdom
-
Sheffield, United Kingdom
-
-
-
-
California
-
Orange, California, United States
-
-
District of Columbia
-
Washington, District of Columbia, United States
-
-
Georgia
-
Augusta, Georgia, United States
-
-
Illinois
-
Maywood, Illinois, United States
-
-
Kentucky
-
Louisville, Kentucky, United States
-
-
Louisiana
-
Shreveport, Louisiana, United States
-
-
Michigan
-
Lansing, Michigan, United States
-
-
Nebraska
-
Omaha, Nebraska, United States
-
-
New York
-
Brooklyn, New York, United States
-
-
Ohio
-
Toledo, Ohio, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 10 months (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must need a feeding tube in place for enteral alimentation (complete or partial) and be in a neonatal intensive care unit or step down unit
- Patients participating in the pHmetry assessment must be in need of this assessment
- New born, neonate or pre-term infants less than 44 weeks with a minimum weight of 0.8 kg and with a presumptive diagnosis of GERD
- Patients who have been treated with, or are currently receiving a proton pump inhibitor (PPI), H2-blockers or antacids
- Patients should be generally healthy, other than for the presence of GERD.
Exclusion Criteria:
- A history of or current clinically significant medical illness (excluding GERD, asthma, reactive airway disease or cystic fibrosis-dependant GERD)
- Continuous drip tube feeding with formula or breast milk
- Patients whose mothers are taking PPIs and who are pumping breast milk to be fed to their infants
- Continuous positive airway pressure (CPAP) delivered via nasal prong or oral mask
- Serum concentrations of hepatic transaminases > 3-fold higher than the upper limit of normal for age creatinine values = 106 micromoles/L
- Clinically relevant abnormal laboratory values
- Treatment with full therapeutic doses of sucralfate or any medication that affects gastrointestinal motility such as baclofen, erythromycin, metoclopramide, cisapride, or domperidone
- A history of allergy or sensitivity to PPIs or to their inactive ingredients
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rabeprazole sodium
|
One single daily dose of rabeprazole sodium 1 mg as a microgranule formulation for up to 28 consecutive days (Part 1), and one single daily dose of rabeprazole sodium 2 or 3 mg as a microgranule formulation for up to 28 consecutive days (Part 2).
The study drug will be administered through a nasogastric or orogastric tube.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rabeprazole plasma concentrations (Parts 1 and 2)
Time Frame: Up to Day 5
|
Up to Day 5
|
Thioether metabolite plasma concentrations (Parts 1 and 2)
Time Frame: Up to Day 5
|
Up to Day 5
|
The change from baseline in intraesophageal H+ concentration (Parts 1 and 2)
Time Frame: Baseline, Day 5
|
Baseline, Day 5
|
The change from baseline in intragastric H+ concentration (Parts 1 and 2)
Time Frame: Baseline, Day 5
|
Baseline, Day 5
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number of patients with adverse events as a measure of safety and tolerability
Time Frame: Approximately 8 weeks
|
Approximately 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2009
Primary Completion (Actual)
December 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
March 2, 2009
First Submitted That Met QC Criteria
March 3, 2009
First Posted (Estimate)
March 4, 2009
Study Record Updates
Last Update Posted (Estimate)
April 29, 2013
Last Update Submitted That Met QC Criteria
April 26, 2013
Last Verified
April 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Gastroenteritis
- Intestinal Diseases
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Esophagitis
- Peptic Ulcer
- Duodenal Diseases
- Gastroesophageal Reflux
- Esophagitis, Peptic
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Rabeprazole
Other Study ID Numbers
- CR014824
- RABGRD1005 (Other Identifier: Janssen Research & Development, LLC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroesophageal Reflux
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroesophageal Reflux Disease | GERD | Acid Reflux | RefluxUnited States
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
TakedaTerminatedGastroesophageal Reflux Disease | Non-erosive Reflux DiseaseSwitzerland, Netherlands
-
Klinikum Garmisch-PatenkirchenNot yet recruitingReflux, Gastroesophageal | Gastro-esophageal RefluxGermany
-
Mansoura UniversityWithdrawnGastroesophageal Reflux Disease
-
Cliniques universitaires Saint-Luc- Université...UnknownGastroesophageal Reflux DiseaseBelgium
-
King Chulalongkorn Memorial HospitalCompleted
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedGastroesophageal Reflux Disease (GERD) | RefluxUnited States, Canada
-
Vanderbilt University Medical CenterCompletedGastroesophageal Reflux Disease (GERD) | Non-erosive Reflux Disease (NERD)United States
Clinical Trials on Rabeprazole sodium
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Eisai Co., Ltd.Completed
-
Janssen Research & Development, LLCEisai Inc.CompletedGastroesophageal Reflux Disease (GERD)United States, Poland, United Kingdom, Belgium, Brazil
-
Eisai Inc.CompletedSymptomatic Gastroesophageal Reflux Disease (sGERD)United States
-
Yungjin Pharm. Co., Ltd.Seoul National University HospitalCompletedGastroesophageal Reflux DiseaseKorea, Republic of
-
Johnson & Johnson Pharmaceutical Research & Development...Eisai Inc.CompletedGastroesophageal RefluxUnited States, Belgium, Israel, Poland, Australia, Netherlands, South Africa, Hungary, Bulgaria, Denmark
-
Zeria PharmaceuticalCompleted
-
Zeria PharmaceuticalCompleted
-
Sihuan Pharmaceutical Holdings Group Ltd.Completed